muscular dystrophy
Santhera announces Early Access Program by partner Sperogenix for DMD treatment
June 11, 2024Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera
Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …
Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment
May 14, 2024Research and Development Musculo-skeletal disorder, Sanofi, collaboration, fulcrum therapeutics, muscular dystrophy
Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with Sanofi for the development and …
Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E
October 7, 2019Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta
Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …
Shares at Sarepta Therapeutics jump after FDA delay in drug approval review
May 26, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment
Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …
The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?
January 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs
The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …
Prosensa and GSK add to muscular dystrophy alliance
June 23, 2010Research and Development GlaxoSmithKline, Prosensa, muscular dystrophy
GSK has extended its research alliance with biotech company Prosensa in the field of muscular dystrophy. Netherlands-based Prosensa focuses on …
Latest content
FibroFind appoints Lee Borthwick as CEO
